These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
571 related articles for article (PubMed ID: 8536448)
1. Effect of testosterone enanthate on serum lipoproteins in man. Anderson RA; Wallace EM; Wu FC Contraception; 1995 Aug; 52(2):115-9. PubMed ID: 8536448 [TBL] [Abstract][Full Text] [Related]
2. Comparison between testosterone enanthate-induced azoospermia and oligozoospermia in a male contraceptive study. I: Plasma luteinizing hormone, follicle stimulating hormone, testosterone, estradiol, and inhibin concentrations. Wallace EM; Gow SM; Wu FC J Clin Endocrinol Metab; 1993 Jul; 77(1):290-3. PubMed ID: 8325955 [TBL] [Abstract][Full Text] [Related]
3. Oral contraceptive tablets containing 20 and 30 micrograms of ethinyl estradiol with 150 micrograms desogestrel. Their influence on lipids, lipoproteins, sex hormone binding globulin and testosterone. Akerlund M; Almström E; Högstedt S; Nabrink M Acta Obstet Gynecol Scand; 1994 Feb; 73(2):136-43. PubMed ID: 8116352 [TBL] [Abstract][Full Text] [Related]
4. Testosterone enanthate at a dose of 200 mg/week decreases HDL-cholesterol levels in healthy men. Meriggiola MC; Marcovina S; Paulsen CA; Bremner WJ Int J Androl; 1995 Oct; 18(5):237-42. PubMed ID: 8567093 [TBL] [Abstract][Full Text] [Related]
5. Comparison between testosterone enanthate-induced azoospermia and oligozoospermia in a male contraceptive study. III. Higher 5 alpha-reductase activity in oligozoospermic men administered supraphysiological doses of testosterone. Anderson RA; Wallace AM; Wu FC J Clin Endocrinol Metab; 1996 Mar; 81(3):902-8. PubMed ID: 8772548 [TBL] [Abstract][Full Text] [Related]
6. Comparison between testosterone enanthate-induced azoospermia and oligozoospermia in a male contraceptive study. II. Pharmacokinetics and pharmacodynamics of once weekly administration of testosterone enanthate. Anderson RA; Wu FC J Clin Endocrinol Metab; 1996 Mar; 81(3):896-901. PubMed ID: 8772547 [TBL] [Abstract][Full Text] [Related]
7. Influence of various modes of androgen substitution on serum lipids and lipoproteins in hypogonadal men. Jockenhövel F; Bullmann C; Schubert M; Vogel E; Reinhardt W; Reinwein D; Müller-Wieland D; Krone W Metabolism; 1999 May; 48(5):590-6. PubMed ID: 10337859 [TBL] [Abstract][Full Text] [Related]
8. Potential of testosterone buciclate for male contraception: endocrine differences between responders and nonresponders. Behre HM; Baus S; Kliesch S; Keck C; Simoni M; Nieschlag E J Clin Endocrinol Metab; 1995 Aug; 80(8):2394-403. PubMed ID: 7543113 [TBL] [Abstract][Full Text] [Related]
9. Transient reduction in serum HDL-cholesterol following medroxyprogesterone acetate and testosterone cypionate administration to healthy men. Friedl KE; Plymate SR; Paulsen CA Contraception; 1985 Apr; 31(4):409-20. PubMed ID: 3159547 [TBL] [Abstract][Full Text] [Related]
10. Effects of long-term use of testosterone enanthate. II. Effects on lipids, high and low density lipoprotein cholesterol and liver function parameters. Tyagi A; Rajalakshmi M; Jeyaraj DA; Sharma RS; Bajaj JS Int J Androl; 1999 Dec; 22(6):347-55. PubMed ID: 10624603 [TBL] [Abstract][Full Text] [Related]
11. Effects of testosterone enanthate in normal men: experience from a multicenter contraceptive efficacy study. World Health Organization Task Force on Methods for the Regulation of Male Fertility. Wu FC; Farley TM; Peregoudov A; Waites GM Fertil Steril; 1996 Mar; 65(3):626-36. PubMed ID: 8774299 [TBL] [Abstract][Full Text] [Related]
12. Lipid effects of an intrauterine levonorgestrel device or oral vs. vaginal natural progesterone in post-menopausal women treated with percutaneous estradiol. Suvanto-Luukkonen E; Sundström H; Penttinen J; Kauppila A Arch Gynecol Obstet; 1998; 261(4):201-8. PubMed ID: 9789651 [TBL] [Abstract][Full Text] [Related]
13. High-density lipoprotein cholesterol is not decreased if an aromatizable androgen is administered. Friedl KE; Hannan CJ; Jones RE; Plymate SR Metabolism; 1990 Jan; 39(1):69-74. PubMed ID: 2294373 [TBL] [Abstract][Full Text] [Related]
14. A cross-over study of three oral contraceptives containing ethinyloestradiol and either desogestrel or levonorgestrel. Song S; Chen JK; Yang PJ; He ML; Li LM; Fan BC; Rekers H; Fotherby K Contraception; 1992 Jun; 45(6):523-32. PubMed ID: 1535580 [TBL] [Abstract][Full Text] [Related]
15. Effects of long-term administration of an oral contraceptive containing ethinylestradiol and cyproterone acetate on lipid metabolism in women with polycystic ovary syndrome. Falsetti L; Pasinetti E Acta Obstet Gynecol Scand; 1995 Jan; 74(1):56-60. PubMed ID: 7856434 [TBL] [Abstract][Full Text] [Related]
16. Combined administration of levonorgestrel and testosterone induces more rapid and effective suppression of spermatogenesis than testosterone alone: a promising male contraceptive approach. Bebb RA; Anawalt BD; Christensen RB; Paulsen CA; Bremner WJ; Matsumoto AM J Clin Endocrinol Metab; 1996 Feb; 81(2):757-62. PubMed ID: 8636300 [TBL] [Abstract][Full Text] [Related]
17. Induction of azoospermia in normal men with combined Nal-Glu gonadotropin-releasing hormone antagonist and testosterone enanthate. Tom L; Bhasin S; Salameh W; Steiner B; Peterson M; Sokol RZ; Rivier J; Vale W; Swerdloff RS J Clin Endocrinol Metab; 1992 Aug; 75(2):476-83. PubMed ID: 1639948 [TBL] [Abstract][Full Text] [Related]
18. Beneficial effects of testosterone undecanoate on the lipoprotein profiles in healthy elderly men. A placebo controlled study. Uyanik BS; Ari Z; Gümüs B; Yiğitoğlu MR; Arslan T Jpn Heart J; 1997 Jan; 38(1):73-82. PubMed ID: 9186283 [TBL] [Abstract][Full Text] [Related]
19. Effects of desogestrel and gestodene in low-dose oral contraceptive combinations on lipid and lipoprotein status. A randomized prospective study. Granata A; Sobbrio GA; D'Arrigo F; Barillari M; Curasì MP; Egitto M; Trimarchi F; Granese D; Pullè C Acta Eur Fertil; 1990; 21(3):143-6. PubMed ID: 2149913 [TBL] [Abstract][Full Text] [Related]
20. Levonorgestrel implants (Norplant II) for male contraception clinical trials: combination with transdermal and injectable testosterone. Gonzalo IT; Swerdloff RS; Nelson AL; Clevenger B; Garcia R; Berman N; Wang C J Clin Endocrinol Metab; 2002 Aug; 87(8):3562-72. PubMed ID: 12161475 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]